MindMed announces successful discussions with the FDA involving its MindMed Session Monitoring System device for clinical use.
Exploring the companies and themes that make up this emerging and exciting new sector
More Outstanding Results With Psychedelics Research, Even More Outstanding Value For Investors
GH Research just released outstanding clinical results for its psychedelic-assisted therapy for TRD. Markets badly mis-pricing these stocks at present.
MINDCURE's iSTRYM Platform: Psychedelics Penetration Is Only The Beginning
MINDCURE's iSTRYM digital therapeutics platform is a first-mover in supplying this critical IT to mental health treatment. But that's only the beginning of its potential.
The 5 Best Values In Psychedelic Stocks
Psychedelic stocks have recently been punished by the market. The flip-side is that many well-capitalized companies now offer spectacular value propositions.
Ketamine Wellness Centers (KWC) Announces Plans to Expand Operations into Salt Lake City and Reno
Delic Holding Corp's subsidiary, Ketamine Wellness Centers, is planning to open two new clinics, in Salt Lake City, Utah
DEA Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT
The Drug Enforcement Administration (DEA) has yet again increased its quota for the legal production of illegal controlled substances like psilocybin, MDMA and DMT for research purposes in 2022.
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways provides further details on its Phase IIb results for the treatment of Treatment Resistant Depression, including reporting of additional "patient improvements".
Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America's First Integrative Mental Health Clinic Network
Novamind expands its treatment footprint via a new partnership with Uruguay-based Bienstar Wellness.
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Cybin seeks FDA approval for a new Phase 2 clinical trial aimed at treating "distress" among frontline healthcare practitioners.
Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing
UK-based Albert Labs receives conditional approval from the Canadian Securities Exchange (CSE) to commence trading under the symbol "ABRT". Trading expected to commence in early 2022.
Red Light Holland Reports Second Quarter 2021 Results
Red Light Holland reports its results for Q2 fiscal 2021. - Quarterly revenues up to CAD$485,738 - A 64% increase in gross profit - 56% increase in the number of retail outlets selling TRIP products
Novamind Reports Fiscal Q1 Financial Results and Operating Highlights
Novamind reports revenues of CAD$1.86 million for Q1 fiscal 2022, a 113% year-over-year increase. The company has total working capital of CAD$6.8 million